Barclays keeps CHF 93.00 target for Sandoz stock

Published on 10/14/2026 at 16:52 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Sandoz trades at 58.41 times earnings and CHF 31.7 billion value. Sandoz stock costs EUR 78.76 on October 14, 2026 at 4:50 p.m. CEST.

Analyst target and market metrics

Barclays maintained a Buy rating and a CHF 93.00 target for Sandoz on October 12, 2026.
Sandoz carried a P/E ratio of 58.41 and a market capitalization of CHF 31.7 billion on October 14, 2026.
Sandoz stock costs EUR 78.76 at Lang & Schwarz on October 14, 2026 at 4:50 p.m. CEST; the SIX quote was CHF 73.42, plus 3.47 percent versus CHF 70.96.

Sandoz, CH1243598427, Illustration mit AI erstellt.

Barclays maintained a Buy rating and a CHF 93.00 target for Sandoz on October 12, 2026, according to Markets Insider. Against the SIX quote of CHF 73.42 at 4:28 p.m. CEST on October 14, 2026, that target lies 26.67 percent above the share price.

Target sits above SIX quote

The Barclays target gives the stock a clearly defined valuation marker in Swiss francs, while the live euro quotation provides the reference for German-market trading. The gap is calculated against the same-currency SIX price, not against the EUR quotation.

The SIX quote stood at CHF 73.42, up 3.47 percent from CHF 70.96 on October 14, 2026. That move places the Swiss listing above its previous session level, while the Lang & Schwarz quotation offers a separate euro view for investors trading outside the home market.

Price and valuation metrics

Sandoz was valued at CHF 31.7 billion on October 14, 2026. Its P/E ratio was 58.41 and its trailing dividend yield was 0.01 percent, giving the valuation a stronger earnings focus than an income focus.

The company operates in Healthcare and the specialty and generic drug manufacturing industry. Its portfolio includes generic medicines, biosimilars, finished dosage forms and biotechnology manufacturing services, with anti-infective ingredients among its established activities.

Comparison with peers

Sandoz (SIX, CHF): plus 3.47 percent, P/E 58.41, market capitalization CHF 31.7 billion

Novartis (NYSE, USD): plus 2.02 percent, P/E 22.24, market capitalization USD 276.1 billion

Teva Pharmaceutical Industries (NYSE, USD): plus 0.78 percent, P/E 69.61, market capitalization USD 48.4 billion

Euro quotation for German investors

Sandoz stock was trading at EUR 78.76 at Lang & Schwarz on October 14, 2026 at 4:50 p.m. CEST. The quote is an intraday euro valuation, while the SIX figures above remain in Swiss francs and are not combined with it.

The further course of trading is shown by the continuously updated real-time quote of Sandoz stock.